QuickView for CYP1B1;jsessionid=3953E34A356F416CB15FC0085D20B0B2;jsessionid=2A57CC5D28963498F55BAEFE5E06AEA1;jsessionid=E1215EEE49586831C4BE0D45548B777E;jsessionid=0F261020DE34FF4595A18F5DFB33450D;jsessionid=80048F17795DCE4B3064143C6BAAFB3B;jsessionid=34F5919144EC32D28FE9299F0511E062;jsessionid=69D37F486CE155560861C172BFE34E93;jsessionid=2418623A3FA14A3EDDB9A24ABD26848E (gene)

1. Variable Phenotype of Congenital Corneal Opacities in Biallelic CYP1B1 Pathogenic Variants.
2. Development of novel N-aryl-2,4-bithiazole-2-amine-based CYP1B1 degraders for reversing drug resista…
3. Lower overall survival in male patients with advanced disease undergoing allogeneic hematopoietic st…
4. 17-(R/S)-hydroxyeicosatetraenoic acid (HETE) induces cardiac hypertrophy through the CYP1B1 in enant…
5. Design of Novel 2-Phenylquinazolin-4-amines as Selective CYP1B1 Inhibitors for Overcoming Paclitaxel…

There were no clinical trials for CYP1B1;jsessionid=3953E34A356F416CB15FC0085D20B0B2;jsessionid=2A57CC5D28963498F55BAEFE5E06AEA1;jsessionid=E1215EEE49586831C4BE0D45548B777E;jsessionid=0F261020DE34FF4595A18F5DFB33450D;jsessionid=80048F17795DCE4B3064143C6BAAFB3B;jsessionid=34F5919144EC32D28FE9299F0511E062;jsessionid=69D37F486CE155560861C172BFE34E93;jsessionid=2418623A3FA14A3EDDB9A24ABD26848E